Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

San-Chi Chen

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The American Journal of Medicine|December 3, 2014
Risk of cancer in patients with cholecystitis: a nationwide population-based studyPei-Chang Lee, Yu-Wen Hu, Li-Yu Hu, et al.
Journal of Hepatocellular Carcinoma|December 1, 2025
Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular CarcinomaChien-Hung Lu, Ching-Wen Chang, San-Chi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2022
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and LeiomyosarcomaTom Wei-Wu Chen, Chia-Lang Hsu, Ruey-Long Hong, et al.
The Oncologist|November 20, 2024
Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancerWen-Kuan Huang, Yan-Jei Tang, Chiao-En Wu, et al.
Liver Cancer|July 21, 2025
Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor AblationMing Shun Wu, Wei-Yu Kao, Ming-Feng Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 StudyNai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, et al.
Liver Cancer|October 22, 2024
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for OligoprogressionTsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, et al.
Hepatology International|February 24, 2026
Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablationChing-Wei Chang, Ming-Shun Wu, Wei-Yu Kao, et al.
Journal of Hepatology|September 19, 2025
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker explorationYih-Jyh Lin, Da-Liang Ou, Yung-Yeh Su, et al.
Liver Cancer|April 21, 2025
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific CountriesChoong-Kun Lee, Changhoon Yoo, Jung Yong Hong, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The American Journal of Medicine|December 3, 2014
Risk of cancer in patients with cholecystitis: a nationwide population-based studyPei-Chang Lee, Yu-Wen Hu, Li-Yu Hu, et al.
Journal of Hepatocellular Carcinoma|December 1, 2025
Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular CarcinomaChien-Hung Lu, Ching-Wen Chang, San-Chi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2022
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and LeiomyosarcomaTom Wei-Wu Chen, Chia-Lang Hsu, Ruey-Long Hong, et al.
The Oncologist|November 20, 2024
Real-world effectiveness and prognostic factors of durvalumab plus chemotherapy in a multicentric cohort with advanced biliary tract cancerWen-Kuan Huang, Yan-Jei Tang, Chiao-En Wu, et al.
Liver Cancer|July 21, 2025
Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor AblationMing Shun Wu, Wei-Yu Kao, Ming-Feng Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 StudyNai-Jung Chiang, Kien Thiam Tan, Li-Yuan Bai, et al.
Liver Cancer|October 22, 2024
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for OligoprogressionTsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, et al.
Hepatology International|February 24, 2026
Taiwan Academy of Tumor Ablation (TATA) consensus on hepatocellular carcinoma ablationChing-Wei Chang, Ming-Shun Wu, Wei-Yu Kao, et al.
Journal of Hepatology|September 19, 2025
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker explorationYih-Jyh Lin, Da-Liang Ou, Yung-Yeh Su, et al.
Liver Cancer|April 21, 2025
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific CountriesChoong-Kun Lee, Changhoon Yoo, Jung Yong Hong, et al.
Pageof 7